Summit Therapeutics Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax in USD from Q2 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Summit Therapeutics Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q2 2019 to Q3 2024.
  • Summit Therapeutics Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending September 30, 2024 was $0.000.
  • Summit Therapeutics Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $0.000, a 100% decline from 2022.
  • Summit Therapeutics Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $705K, a 61% decline from 2021.
  • Summit Therapeutics Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $1.81M, a 110% increase from 2020.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $0 $0 Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q4 2023 $0 $0 $0 Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $0 $0 -$220K -100% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $220K $0 -$235K -100% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $455K $0 -$250K -100% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $705K $0 -$251K -100% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $956K $220K -$1.09M -83.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $2.05M $235K +$178K +312% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $1.87M $250K +$58K +30.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $1.81M $251K +$66K +35.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $1.74M $1.31M +$1.13M +623% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $615K $57K -$113K -66.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $728K $192K -$132K -40.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 $860K $185K Oct 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
Q3 2020 $181K +$33K +22.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $170K +$14K +8.97% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $324K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q3 2019 $148K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $156K Apr 1, 2019 Jun 30, 2019 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.